Skip to content

A Block-Randomized, Multicenter Clinical Study Evaluating the Efficacy and Safety of Three Miao Medicine Therapies (Scraping Therapy, Medicated Paper Moxibustion, and Jade Pestle Acupoint Therapy) as Adjuvant Treatments for Local Pain in Cervical Spondylosis, Using Diclofenac Sodium Gel as Control

A Block-Randomized, Multicenter Clinical Study Evaluating the Efficacy and Safety of Three Miao Medicine Therapies (Scraping Therapy, Medicated Paper Moxibustion, and Jade Pestle Acupoint Therapy) as Adjuvant Treatments for Local Pain in Cervical Spondylosis, Using Diclofenac Sodium Gel as Control

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001463
Enrollment
Unknown
Registered
2026-06-10
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical spondylosis

Interventions

Experimental Group A:Miao Medicine Scraping Therapy
Trial Group B:Miao Medicine Medicated Paper Moxibustion Therapy
Experimental Group C:Miao Medicine Jade Pestle Acupressure Therapy
Control Group:Diclofenac Sodium Gel

Sponsors

Guizhou University of Traditional Chinese Medicine First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet Western medical diagnostic criteria for cervical spondylotic radiculopathy; (2) Meet TCM diagnostic criteria for wind-cold obstruction syndrome; (3) NRS pain score 4-7 points, assessed as suitable for relief through external therapy alone; (4) Age 18-65 years; (5) Patients who agree to participate and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Non-degenerative cervical conditions with upper limb numbness/pain (e.g., thoracic outlet syndrome, carpal tunnel syndrome); (2) Suspected spinal injury with spinal cord damage; (3) Developmental spinal stenosis (spinal canal ratio = sagittal diameter of spinal canal/sagittal diameter of vertebral body <0.75); (4) Previous cervical surgery or cervical deformity; (5) Coagulation disorders (hemophilia, thrombocytopenia, leukemia); (6) Skin lesions, ulcers, abscesses, or severe dermatosis (e.g., psoriasis) at treatment site; (7) Severe cardiovascular/cerebrovascular diseases, hepatic/renal failure, acute infectious diseases, malignancies; (8) Extreme hunger, fatigue, intoxication, hypoglycemia, or recent convalescence; (9) Diabetes, uncontrolled hypertension, or hypertensive crisis; (10) Yin deficiency with effulgent fire or high fever; (11) History of alcohol/drug abuse; (12) Psychiatric disorders; (13) Pregnant or pregnancy-planning patients; (14) Allergic constitution or hypersensitivity to study medications; (15) Participation in other clinical trials within 1 month.

Design outcomes

Primary

MeasureTime frame
Pain Relief Rate After 7 Days of Treatment, defined as a reduction of 3 points or more on the Numerical Rating Scale;

Secondary

MeasureTime frame
Numerical Rating Scale Scores Before and After First Treatment;Numerical Rating Scale Scores at 3 Days and 7 Days of Treatment;

Countries

China

Contacts

Public ContactXia Jingfu

Guizhou University of Traditional Chinese Medicine First Affiliated Hospital

xiajingfu2021@163.com18096168735

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026